Drug details
Ogivri (trastuzumab-dkst injection, for intravenous use)
type of Antineoplastics, Anti-HER2
Ogivri (trastuzumab-dkst) is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- nausea,
- itching,
- vomiting,
- diarrhea,
- fever,
- easy bruising,
- unusual bleeding,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- chills,
- tiredness,
- chest pain,
- dizziness,
- severe headache,
- blurred vision,
- pounding in your neck or ears,
- headache,
- weakness,
- trouble swallowing,
- muscle cramps,
- rapid weight gain,
- pounding heartbeats,
- new or worsening cough,
- swelling in your lower legs,
- skin sores,
- red or swollen gums,
- tingling in your hands and feet or around your mouth
- fast or slow heart rate, and
- blisters or ulcers in your mouth,
The following drugs are related to Ogivri, either as a replacement or used together:
- Delestrogen (estradiol valerate)
- Depo-Estradiol (estradiol cypionate injection)
- Femring (estradiol acetate)
- Estrasorb (estradiol topical emulsion)
- Vivelle-Dot (estradiol transdermal system)
- Soltamox (tamoxifen citrate)
- Tukysa (tucatinib tablets)